Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 10/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25360592 | 1.00 | FURIN (0.37) | FURINC3AR1SMN1; SMN2ROCK2MAP1LC3B | |
| SCHEMBL25360917 | 0.94 | FURIN (0.35) | FURINC3AR1SMN1; SMN2ROCK2MAP1LC3B | |
| SCHEMBL24395307 | 0.94 | FURIN (0.35) | FURINC3AR1SMN1; SMN2ROCK2MAP1LC3B | |
| SCHEMBL26026790 | 0.90 | FURIN (0.38) | FURINSMN1; SMN2ROCK2MAP1LC3BHTT | |
| SCHEMBL25363100 | 0.90 | FURIN (0.38) | FURINSMN1; SMN2ROCK2MAP1LC3BHTT | |
| SCHEMBL25363108 | 0.90 | FURIN (0.38) | FURINSMN1; SMN2ROCK2MAP1LC3BHTT | |
| SCHEMBL25361709 | 0.90 | FURIN (0.37) | FURINC3AR1SMN1; SMN2ROCK2MAP1LC3B | |
| SCHEMBL25360798 | 0.90 | FURIN (0.37) | FURINC3AR1SMN1; SMN2ROCK2MAP1LC3B | |
| SCHEMBL29528370 | 0.89 | FURIN (0.40) | FURINSMN1; SMN2ROCK2MAP1LC3BHTT | |
| SCHEMBL29623561 | 0.89 | FURIN (0.40) | FURINSMN1; SMN2ROCK2MAP1LC3BHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | FURIN 2087/4885C3AR1 3148/4885SMN1; SMN2 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.